Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01966666 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01966666 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 29 participants.
The verdict
NCT01966666, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the highest dose of TPI-287 that is safe and tolerable when administered as an intravenous infusion to participants with mild to moderate Alzheimer's disease (AD), to measure pharmacokinetic properties of the drug as well as to gauge preliminary efficacy of TPI-287 on disease progression.
Interventions
- DRUG Placebo
- DRUG TPI-287 20 mg/m2
- DRUG TPI-287 6.3 mg/m2
- DRUG TPI-287 2 mg/m2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2013-11 |
| Est. Completion | 2019-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01966666
The ClinicalTrials.gov registry entry for NCT01966666 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01966666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01966666 about?
NCT01966666 is a clinical study titled "A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease". The purpose of the study is to determine the highest dose of TPI-287 that is safe and tolerable when administered as an intravenous infusion to participants with mild to moderate Alzheimer's disease (AD), to measure pharmacokinetic properties of the drug as well as to gauge preliminary efficacy of T...
What is the current status of trial NCT01966666?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2013-11. Estimated completion is 2019-09.
What interventions are being tested in trial NCT01966666?
The interventions under investigation include: Placebo (DRUG), TPI-287 20 mg/m2 (DRUG), TPI-287 6.3 mg/m2 (DRUG), TPI-287 2 mg/m2 (DRUG).
Who is sponsoring clinical trial NCT01966666?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.